HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer.

Abstract
Fourteen patients with advanced carcinoma of the breast were treated with CAP combination therapy. An objective therapeutic response (partial remissions with a mean duration of 6.3 months) was achieved in 6 of 13 evaluated patients. This response was observed in soft tissue metastases. Nausea and vomiting were found to be the most frequent undesirable side effects in all patients and could not be avoided by administration of antiemetics. In 2 patients mild nephrotoxicity was found without any effects on further therapy. The results of this study were considered as promising; a definitive assessment of the CAP regimen is expected to come from a randomized study which started in the CMEA countries in 1983.
AuthorsZ Mechl, B Sopková
JournalNeoplasma (Neoplasma) Vol. 31 Issue 4 Pg. 431-5 ( 1984) ISSN: 0028-2685 [Print] Slovakia
PMID6547999 (Publication Type: Journal Article)
Chemical References
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use, toxicity)
  • Breast Neoplasms (drug therapy)
  • Cisplatin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Drug Evaluation
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: